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ABSTRACT 
  
Longitudinal interaction between APOA5 -1131T>C 
and overweight in the acceleration of age-related 
increase in arterial stiffness through the regulation of 
circulating triglycerides 
 
Hwa Jin Lee 
Department of Science for Aging  
The Graduate School 
Yonsei University 
 
 
 
The aim of this study was to evaluate whether the longitudinal interaction between 
APOA5 -1131C variants and overweight could accelerate age-related increases in 
arterial stiffness and circulating triglycerides (TG) in healthy subjects. Brachial-ankle 
pulse wave velocity (baPWV) was measured in 503 healthy subjects at baseline and 
within a mean follow-up period of 3 years. triglycerides, APOA5 -1131T>C SNPs, 
apolipoprotein (apo) A-V levels and low density lipoprotein (LDL) particle size were 
vii 
measured. At the 3-year follow-up, the overweight group with the C allele showed 
increases in triglycerides and brachial-ankle pulse wave velocity relative to the 
baseline. Additionally, in the overweight group, there was a genotype effect on the 
changes in triglycerides: subjects with the C allele had greater increases in triglyceride 
concentrations than those with the TT genotype. Furthermore, overweight subjects with 
the C allele had greater increases in triglycerides concentrations than normal-weight 
subjects with the C allele (P-interaction=0.013). Overweight subjects with the C allele 
had greater increases in brachial-ankle pulse wave velocity than normal-weight 
subjects with the C allele (P-interaction=0.047). Changes in brachial-ankle pulse wave 
velocity were affected by age, baseline brachial-ankle pulse wave velocity, and changes 
in systolic blood pressure (BP) and triglycerides. Changes in triglycerides were 
affected by the APOA5 -1131T>C genotype, age, baseline triglyceride levels, and 
changes in body mass index (BMI) and apolipoprotein A-V. In the overweight group, 
changes in brachial-ankle pulse wave velocity were affected by changes in systolic 
blood pressure, low density lipoprotein particle size and triglyceride. This prospective 
study shows that the interactive effect between APOA5 -1131C variants and 
overweight can accelerate age-related increase in arterial stiffness through the 
regulation of circulating triglycerides in healthy subjects. 
 
 
Keywords : APOA5; arterial stiffness; gene-environment interaction; overweight; 
triglycerides 
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1. INTRODUCTION 
 
The APOA5 gene, encoding apolipoprotein (apo) A-V, is one of the major genetic 
determinants of circulating triglycerides (TG) levels, as demonstrated in animal models 
[1]. In humans, both single-gene and genome-wide association studies in different 
populations have confirmed the importance of APOA5 in affecting TG concentrations 
[2,3]. Circulating TG levels, which are also affected by overweight/obesity and insulin 
resistance [4], are a risk factor for atherosclerosis [5] and can initiate atherogenic 
dyslipidemia [6].  
In clinical practice, pulse wave velocity (PWV) is widely used to reflect arterial 
stiffness, an index of atherosclerosis [7,8]. Brachial-ankle pulse wave velocity (baPWV) 
measurements, which are easier to perform than carotid-femoral PWV measurements, 
have been used as a marker to screen for vascular damage and cardiovascular risk in 
the general population [7,9]. A cardiovascular outcome resulting from 
hypertriglyceridemia is arterial stiffness, a pathological condition associated with 
vascular damage [7]. An inverse relationship between plasma TG and plasma apo A-V 
and between hepatic APOA5 expression and plasma TG levels has been described in an 
animal-model study [1], whereas an unexpected and significant positive correlation 
between circulating apo A-V and TG levels in men and women has been demonstrated 
[10,11]. This difference might be because most human studies examining the 
relationship between apo A-V and TG are cross-sectional. 
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Arterial stiffness increases with age, but the longitudinal interaction between 
genetic and environmental factors that might influence its progression are unknown. 
Thus, studies exploring the longitudinal effect of APOA5 -1131T>C on the age-related 
progression of arterial stiffness and circulating concentrations of TG and apo A-V are 
necessary. In this study, the examined whether the longitudinal interaction between 
APOA5 -1131T>C (TT vs C allele) and body weight (normal weight vs overweight) 
affects the age-related progression of arterial stiffness and the circulating levels of TG 
and apo A-V of healthy subjects. 
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2. BACKGROUND 
 
2.1. Apolipoprotein A5 gene 
Apolipoprotein A5 gene (APOA5) is located in the apolipoprotein APOA1/C3/A4 
gene on chromosome 11q23 [12,13]. APOA5 is mainly expressed in liver cells and 
secreted into the plasma [13,14]. The APOA5 is important function in the metabolism 
of TG [15]. Increased level of APOA5 is correlated with decreased TG concentration in 
the plasma [15]. Polymorphisms in the APOA5 gene are strongly affected by TG levels 
[2]. Among the genetic variants associated with the expansion of hyperlipidemia there 
is a natural variant (-1131T>C) in the promoter region of APOA5 gene [2]. 
Mice expressing a human APOA5 transgene showed a decrease in plasma TG 
concentrations to one-third of those in control mice, reversely knockout mice lacking 
APOA5 had four times as much plasma TG as controls [2]. In humans, single 
nucleotide polymorphisms (SNPs) across the APOA5 locus were found to be 
significantly associated with plasma TG levels in two independent studies [2]. These 
findings indicate that APOA5 is an important determinant of plasma TG levels, a major 
risk factor for coronary artery disease [2].  
The -1131T>C polymorphism in the newly identified APOA5 gene has been 
associated with elevated plasma TG [16]. It has been shown for other genes that the 
effect of polymorphisms on plasma TG is modulated by body mass index (BMI) [17]. 
Study participants were divided into normal weight (BMI≤25 kg/m2) and overweight 
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(BMI>25 kg/m2) [16]. There was no significant difference TG level between carriers 
and noncarriers among normal-weight subjects, but in overweight subjects the level in 
carriers was very significantly higher than in noncarriers [16]. 
 
2.2. Brachial-ankle pulse wave velocity  
In clinical practice, PWV is widely used to reflect arterial stiffness [7,8]. A 
noninvasive baPWV measurement, which is performed more easily than 
carotidfemoral PWV measurement, has been used as a marker for screening vascular 
damage and cardiovascular risk in the general population [18,19], in diabetes patients 
[20,21], in hypertension patients [22,23], in patients with end-stage renal disease 
[24,25], and in women with systemic lupus erythematosus [26]. 
The baPWV was assessed in a supine position after 5 minutes of bed rest [27]. 
Pneumonic cuffs were wrapped around both upper arm (brachial artery) and ankles 
(tibial artery) and connected to a plethysmographic sensor to determine the volume 
pulse waveform [27]. Waveforms were stored for 10-second sample times with 
automatic gain analysis and quality adjustment [27]. Requires simply placing blood 
pressure cuffs on the 4 extremities [27,28].  
The baPWV has been shown to be a marker of atherosclerotic vascular damage or 
cardiovascular risk [7]. The present study conducted to evaluate the validity and 
reproducibility of noninvasive baPWV measurements and to examine the alteration of 
baPWV in patients with coronary artery disease (CAD) [29]. baPWV were 
significantly higher in CAD patients than in non-CAD patients with risk factors. 
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Furthermore, baPWV were higher in non-CAD patients with risk factors than in 
healthy subjects without risk factors [29]. Thus, the validity and reproducibility of 
baPWV measurements are considerably high, and this method seems to be an 
acceptable marker reflecting vascular damages. baPWV measured is suitable for 
screening vascular damages in a general population [29]. baPWV has been shown to 
increase with aging and hypertension [28].  
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3. MATERIALS AND METHODS 
 
3.1. Subjects 
 
This study was performed a 3-year prospective cohort study that included 800 
heathy subjects (30-65 years old), who underwent triennial medical evaluations at the 
National Health Insurance Corporation Ilsan Hospital in Goyang, Korea during the 
period from January 2008 to December 2013. Of these, 503 nondiabetic and nonobese 
individuals were finally selected. Exclusion criteria included the following: 1) current 
and/or past history of cardiovascular disease, 2) diabetes mellitus (fasting glucose 
levels ≥126 mg/dL), 3) abnormal liver or renal function, 4) thyroid or pituitary disease, 
5) pregnancy or lactation, and 6) regular use of any medication. Before participation, 
the purpose of the study was carefully explained to all participants, and their written 
informed consent was obtained. The study protocol was approved by the Institutional 
Review Board of the National Health Insurance Corporation Ilsan Hospital and Yonsei 
University and was carried out in accordance with the Helsinki Declaration.  
 
3.2. Genotyping of rs662799 (APOA5 -1131T>C) 
Among the five common APOA5 SNPs that have been studied, -1131T>C and 
56C>G (S19W) are considered to be functional tag SNPs [30-32]. However, the S19W 
SNP was monomorphic in the population of this study. Thus, the APOA5 -1131T>C 
SNP was selected as the functional SNP to investigate further [33].  
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DNA was extracted from 5 mL of whole blood using a commercially available DNA 
isolation kit (Promega Corp., Madison, USA) according to the manufacturer’s protocol. 
Genotyping was performed via SNP-IT™ assays using single primer extension 
technology (SNPstream 25K™ System; Orchid BioSciences, NJ, USA).  
 
3.3. Clinical and biochemical assessments 
 
Body weight, height and waist circumference were measured, and BMI was 
calculated in units of kilograms per square meter (kg/m2). Systolic and diastolic blood 
pressure (BP) was assessed in a supine position after a resting period. Blood samples 
were collected following an overnight fast of at least 12 hours.  
Fasting triacylglycerol were measured via enzymatic assay using Pureauto S TG-N 
and Pureauto S CHO-N kits (Daiichi, Tokyo, Japan). Total- and high density 
lipoprotein (HDL) cholesterol was measured via selective inhibition using Cholestest 
N-HDL kits (Daiichi, Tokyo, Japan). Glucose levels were measured via the hexokinase 
method using glucose kits (Siemens, NY, USA), insulin levels were measured via an 
immunoradiometric assay using commercial kits (DIAsource ImmunoAssays S.A., 
Louvainla-Neuve, Belgium). Low density lipoprotein (LDL)  particle size were 
isolated using sequential flotation ultracentrifugation and particle size distribution 
(1.019–1.063 g/mL) examined on non-denaturing polyacrylamide gels containing a 
linear gradient of 2-16 % acrylamide (CBS Scientific, CA, USA) using a pore gradient 
lipoprotein system (CBS Scientific Company Inc., CA, USA), and apo A-V were 
measured by turbidity at 340 nm using specificanti-serum (Roche, Basel, Switzerland).  
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baPWV were measured using an automatic waveform analyzer (model VP-1000;  
Nippon Colin Ltd., Komaki, Japan). 
 
3.4. Statistical analysis 
Statistical analyses were performed using SPSS version 21.0 (IBM/SPSS, Chicago, 
IL, USA). Hardy-Weinberg equilibrium (HWE) was tested for using PLINK version 
1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). Differences in clinical variables 
between two groups (Normal weight vs. Overweight; TT vs. C allele) were tested by 
independent t-test. Paired t-tests were performed to determine the differences at the 3-
year follow-up from the baseline in each group. The interactions between genotype and 
bodyweight were tested using a two-way ANOVA. Multiple linear regression analyses 
were performed to identify major independent predictors of changes in baPWV and TG 
levels. Pearson’s correlation coefficient was used to examine the relationships between 
variables. Heat maps were created to visualize and evaluate the relationships among 
metabolites and the biochemical measurements in the study population. Logarithmic 
transformations were performed on skewed variables. For descriptive purposes, the 
mean values are presented as untransformed values. The results are expressed as the 
means ± standard error (SE). A two-tailed P-value <0.05 was considered statistically 
significant.  
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4. RESULTS 
 
4.1. Distribution of rs662799 (APOA5 -1131T>C) in normal-
weight and overweight subjects 
 
Study participants were divided the cohort into 2 groups: the normal-weight group 
(18.5 kg/m2 ≤ BMI < 25 kg/m2, n=349) and the overweight group (25 kg/m2 ≤ BMI < 
30 kg/m2, n=154). The genotype frequencies did not deviate significantly from Hardy-
Weinberg equilibrium (P > 0.05). The frequencies of the minor alleles of APOA5 -
1131T>C were 0.297 and 0.315 in normal-weight and overweight individuals, 
respectively, which are similar to the values observed in the Korean population [34]. 
Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 
155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C 
allele of the APOA5 -1131T>C polymorphism. Among the 154 overweight individuals, 
68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) 
and 11 were homozygous (CC) for the C allele of the APOA5 -1131T>C 
polymorphism. The pooled the heterozygotes (TC) and rare-allele homozygotes (CC) 
to increase statistical power.  
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4.2. Clinical characteristics and biochemical parameters at 
baseline and the 3-year follow-up 
 
With regard to the APOA5 -1131T>C polymorphism, there were no significant 
differences between the normal-weight and overweight groups at baseline in their age 
and sex distributions across the genotypes (Table 1). Additionally, there were no 
significant differences in smoking or drinking status across the genotypes in the 
normal-weight and overweight groups at baseline and at the 3-year follow-up (data not 
shown).  
In the normal-weight group, there was no APOA5 -1131T>C genotype effect at 
baseline, but at the 3-year follow-up, a genotype-effect was found in relation to HDL 
cholesterol: HDL cholesterol levels were lower in normal-weight individuals with the 
C allele than in those with the TT genotype (Table 1). 
   The overweight group showed higher BMI values, systolic and diastolic BP, and 
glucose and insulin levels and lower HDL cholesterol levels at both baseline and the 3-
year follow-up than the normal-weight group, irrespective of genotype. Overweight 
individuals with the C allele showed higher total cholesterol levels at baseline and a 
smaller LDL particle size at both baseline and the 3-year follow-up. After 3 years, 
overweight C allele carriers showed significant increases in systolic BP and a 
significant decrease in HDL cholesterol relative to baseline. At the 3-year follow-up in 
the overweight group, C allele carriers showed lower HDL cholesterol levels and a 
smaller LDL particle size than TT carriers (Table 1). 
11 
Table 1. Biochemical parameters according to rs662799 (APOA5 -1131 T>C) genotypes at baseline and 3-year follow-
up in healthy individuals with normal weight or overweight 
 
Mean ± SE.∮tested by logarithmic transformation. aP<0.05 comparison between TT and C allele in Normal weight group at baseline. bP<0.05 comparison between TT and C allele in Normal weight 
group at 3 year follow-up. cP<0.05 comparison between TT and C allele in Overweight group at baseline. dP<0.05 comparison between TT and C allele in Overweight group at 3 year follow-up. 
eP<0.05 comparison between TT in Normal weight and Overweight groups at baseline. fP<0.05 comparison between TT in Normal weight and Overweight groups at 3 year follow-up. gP<0.05 
comparison between C allele in Normal weight and Overweight groups at baseline. hP<0.05 comparison between C allele in Normal weight and Overweight groups at 3 year follow-up. iP<0.05 
comparison between TT and C allele in Normal weight group at change values. jP<0.05 comparison between TT and C allele in Overweight group at change values. kP<0.05 comparison between TT 
in Normal weight and Overweight groups at change values. lP<0.05 comparison between C allele in Normal weight and Overweight groups at change values. *P<0.05,**P<0.01,***P<0.001 compared 
with the levels at baseline in each group by paired t-test.
 
Normal weight  Overweight 
TT (n=168)  C allele (n=181)  TT (=68)  C allele (n=86) 
Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Baseline Follow-up 
Baseline age (year) 47.7 ±0.67  47.3 ±0.70  47.6 ±1.14  47.4 ±1.05 
Male/Female n, (%) 76 (45.2) / 92 (54.8)  79 (43.6) / 102 (56.4)  28 (41.2) / 40 (58.8)  41 (47.7) / 45 (52.3) 
BMI (kg/m2) 22.1 ±0.14 22.2 ±0.16  22.0 ±0.14 22.1 ±0.15  26.8 ±0.18e 27.0 ±0.22 f  26.8 ±0.19g 26.7 ±0.23h 
Change 0.10 ±0.08  0.10 ±0.07  0.08 ±0.15  -0.08 ±0.11 
Systolic BP (mmHg) 115.5 ±1.08 116.7 ±1.03  115.2 ±0.90 115.1 ±1.01  121.6 ±1.65e 123.4 ±1.73 f  122.7 ±1.38g 126.1 ±1.35h,* 
Change  1.15 ±0.92    -0.10 ±0.89    1.76 ±1.71    3.35 ±1.34l  
Diastolic BP (mmHg) 70.9 ±0.83 71.8 ±0.81  70.7 ±0.74 71.5 ±0.76  75.2 ±1.22e 76.8 ±1.26 f  75.4 ±1.01g 77.4 ±1.04h 
HDL-cholesterol 
(mg/dL)∮ 
56.3 ±1.08 55.3 ±0.93 
 
53.9 ±1.11 52.0 ±1.05b,* 
 
52.4 ±1.68e 49.0 ±1.53 f,* 
 
47.2 ±1.27c,g 44.6 ±1.16d,h,* 
Total-cholesterol 
(mg/dL)∮ 
187.1 ±2.34 195.0 ±2.45*** 
 
184.8 ±2.43 194.0 ±3.07*** 
 
193.2 ±3.80 195.6 ±4.43 
 
197.7 ±3.42g 200.7 ±3.38 
Glucose (mg/dL)∮ 91.2 ±0.65 92.0 ±0.59  90.0 ±0.64 90.5 ±0.75  95.2 ±1.18e 97.4 ±1.53 f  97.0 ±0.93g 96.7 ±1.22h 
Insulin (μIU/dL)∮ 8.12 ±0.27 7.31 ±0.20*  7.93 ±0.22 7.13 ±0.23***  10.2 ±0.46e 9.72 ±0.51 f  9.77 ±0.42g 9.02 ±0.44h,* 
LDL particle size 
(nm)∮ 
23.8 ±0.07 23.9 ±0.10 
 
23.8 ±0.07 23.8 ±0.08 
 
23.5 ±0.18 23.6 ±0.16 
 
23.3 ±0.14g 23.2 ±0.17d,h 
-11- 
 
- 12 - 
4.3. Interaction between the APOA5 -1131T>C genotype and 
body weight in relation to 3-year changes in TG, apo A-V, 
systolic BP and baPWV 
The effects of the APOA5 -1131T>C genotype on mean changes in TG, apo A-V, 
and baPWV in the normal-weight and overweight groups at 3 years are shown in 
Figure 1. In the normal-weight group, individuals with the C allele showed higher 
serum TG levels than those with the TT genotype. The overweight group showed 
higher serum TG levels at both baseline and the 3-year follow-up than the normal-
weight group, irrespective of genotype. After 3-years, overweight C allele carriers 
showed significant increases in TG and baPWV. At the 3-year follow-up, C allele 
carriers showed higher TG than TT carriers in the overweight group. Furthermore, at 
the 3-year follow-up, overweight TT and C allele carriers showed higher baPWVs than 
normal-weight subjects with the TT and C alleles, respectively (Figure 1). 
There was no significant gene and body weight interaction on the changes in fasting 
apo A-V (Figure 1), BP, HDL and total cholesterol, glucose, insulin, and LDL particle 
size values (data not shown). At the 3-year follow-up, after adjusting for age, sex, 
smoking and drinking, the results show a significant interaction between the APOA5 -
1131T>C genotype and body weight (overweight compared with normal-weight) in 
relation to changes in TG (P for interaction=0.013) and baPWV (P for 
interaction=0.047). In the overweight group, there was an APOA5 -1131T>C genotype 
effect on changes in TG: subjects with the C allele had greater increases in serum TG 
concentrations than did those with the TT genotype; however, this genotypic effect on 
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changes in TG was not observed in normal-weight subjects. Additionally, overweight 
subjects with the C allele had greater increases in their serum TG concentration than 
normal-weight subjects with the C allele. Overweight subjects with the C allele had 
greater increases in baPWV than normal-weight subjects with C allele. Similarly, 
overweight subjects with C allele had greater increase in systolic BP than normal-
weight subjects with C allele (Table 1); however, there was no significant effect of a 
gene × body weight interaction on systolic BP. 
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Figure 1. Genotype effect of APOA5 -1131T>C on changes in TG, LDL particle size, apo A-V, and baPWV by nomal 
weight and overweight groups at 3-year follow-up from baseline. 
Mean ± SE. §tested by logarithmic transformation.aP<0.05 comparison between TT and C allele in Normal weight group at baseline. bP<0.05 comparison between TT and C allele in 
Normal weight group at 3 year follow-up. cP<0.05 comparison between TT and C allele in Overweight group at baseline. dP<0.05 comparison between TT and C allele in 
Overweight group at 3 year follow-up. eP<0.05 comparison between TT in Normal weight and Overweight groups at baseline. fP<0.05 comparison between TT in Normal weight 
and Overweight groups at 3 year follow-up. gP<0.05 comparison between C allele in Normal weight and Overweight groups at baseline. hP<0.05 comparison between C allele in 
Normal weight and Overweight groups at 3 year follow-up. iP<0.05 comparison between TT and C allele in Normal weight group at change values. jP<0.05 comparison between TT 
and C allele in Overweight group at change values. kP<0.05 comparison between TT in Normal weight and Overweight groups at change values. lP<0.05 comparison between C 
allele in Normal weight and Overweight groups at change values. *P<0.05, **P<0.01, ***P<0.001 compared with the levels at baseline in each group by paired t-test.
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4.4. Correlation among changes in BMI, systolic and diastolic 
BP, TG, HDL and total cholesterol, glucose, insulin, LDL 
particle size, apo A-V, and baPWV. 
 
Figure 2 shows the correlation among the changes (differences from baseline) in 
BMI, systolic and diastolic BP, TG, HDL and total cholesterol, glucose, insulin, LDL 
particle size, apo A-V, and baPWV values in the normal-weight and overweight groups 
in relation to the APOA5 -1131T>C genotype. In the normal-weight group with the TT 
genotype, changes in TG correlated positively with changes in BMI, glucose, and 
insulin values and negatively with changes in LDL particle size and apo A-V level 
(P<0.001, Figure 3).  
Changes in baPWV were positively correlated with changes in glucose level and 
systolic and diastolic BP in the normal-weight group with the TT genotype. In the 
normal-weight group with the C allele, changes in TG correlated negatively with 
changes in HDL cholesterol level and LDL particle size and positively with changes in 
BMI, insulin level and baPWV (P=0.011, Figure 3), which was positively correlated 
with changes in systolic and diastolic BP in the normal-weight group with the C allele. 
In the overweight group with the TT genotype, changes in TG were negatively 
correlated with changes in LDL particle size and apo A-V level (P=0.002, Figure 3). 
Changes in baPWV were positively correlated with changes in glucose level and 
systolic and diastolic BP in the normal-weight group with the C allele. In the 
overweight group with the C allele, changes in TG correlated negatively with changes 
in HDL cholesterol and apo A-V levels (P=0.028, Figure 3) and LDL particle size and 
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positively with changes in BMI, insulin level and baPWV (P=0.004, Figure 3), which 
was positively correlated with changes in systolic and diastolic BP in the overweight 
group with the C allele. Other correlations among the changes in clinical and 
biochemical parameters are shown in Figure 2. 
Because the regulation of changes in TG levels is complex, a multiple linear 
regression analysis was performed in all subjects (n=503) to determine the independent 
effects of the following variables on changes in TG: age, APOA5 -1131T>C genotype, 
and baseline TG levels, as well as changes in BMI, systolic and diastolic BP and the 
levels of glucose, insulin, total and HDL cholesterol, and apo A-V. Changes in TG in 
all subjects (n=503) were affected by the APOA5 -1131T>C genotype, age, baseline 
TG level and by changes in BMI and apo A-V level (R2=0.258, P<0.001). In the 
normal-weight group (n=349), changes in TG were affected by baseline TG levels and 
changes in BMI, glucose, apo A-V and systolic BP values (R2=0.286, P=0.034). In the 
overweight group (n=154), changes in TG were affected by baseline TG levels and 
changes in apo A-V levels (R2=0.209, P=0.013). 
Also performed a multiple linear regression analysis including all subjects (n=503) 
to determine the independent effects of the following variables on changes in baPWV: 
age, APOA5 -1131T>C genotype, baseline baPWV, as well as changes in BMI and 
systolic and diastolic BP and in the levels of glucose, insulin, total and HDL 
cholesterol, and apo A-V and LDL particle size. Changes in baPWV in all subjects 
(n=503) were affected by age, baseline baPWV, and changes in systolic BP and TG 
level (R2=0.193, P<0.001). In the normal-weight group (n=349), changes in baPWV 
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were affected by age, baseline baPWV and changes in TG and apo A-V levels 
(R2=0.204, P=0.032). In the overweight group (n=154), changes in baPWV were 
affected by changes in systolic BP, LDL particle size and TG level (R2=0.413, 
P=0.002). 
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Figure 2.  Correlation between changes (∆) in apo A-V and TG and between 
changes in triglyceride and baPWV in normal weight (○) and 
overweight/obese (*) groups according to APOA5 -1131 T>C genotype 
(a) Correlation between changes in apo A-V and TG in TT genotype. (b) Correlation 
between changes in TG and baPWV in TT genotype. (c) Correlation between changes in 
apo A-V and triglyceride in TC+CC genotype. (d) Correlation between changes in TG and 
baPWV in TC+CC genotype. 
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Figure 3.  Correlation matrix among changes in clinical parameters in  
normal weight and overweight/obese groups according to  
APOA5 -1131 T>C genotype 
Correlations were obtained by deriving a Pearson correlation coefficient. Red  
is a positive correlation and Blue is a negative correlation. 
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5. DISCUSSION 
 
Arterial stiffness increases with age, but the interaction between genetic and 
environmental factors that might influence its progression is unknown. This 
prospective study examined the longitudinal interactive effects of APOA5 -1131T>C 
and body weight on circulating TG and the progression rate of arterial stiffness. 
baPWV, which reflects arterial stiffness [9,35] was measured at baseline and re-
examined within a mean follow-up period of 3 years. The main finding of this study is 
that the interactive effect between APOA5 -1131C variants and overweight can 
accelerate the age-related elevation of arterial stiffness through the regulation of 
circulating TG in healthy subjects. 
At 3-years, the overweight group showed higher baPWVs than the normal-weight 
group, without considering genotype, but only the overweight subjects with the C 
allele showed an increase in baPWV over the 3-year period. Therefore, the overweight 
subjects with the C allele had greater increases in baPWV than the normal-weight 
subjects with the C allele. This result suggests that an acceleration in the age-related 
enhancement of arterial stiffness can partly result from a longitudinal interaction 
between APOA5 -1131C variants and overweight. The existence of a strong association 
between the presence of metabolic syndrome, which includes elevated levels of 
circulating TG, and arterial stiffness has been shown in many cross-sectional studies 
[9,36,37] and follow-up studies [7,8,38]. However, the longitudinal effect of 
triglyceride-related genes on arterial stiffness in the general population has not been 
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clarified. 
There was a significant and weakly positive correlation between the changes in TG 
and in baPWV in the normal-weight group with the -1131C allele; however, a strongly 
positive correlation was present between the changes in TG and baPWV in the 
overweight group with -1131C allele. This is partly due to the greater increases in TG 
at the 3-year follow-up in the overweight C allele carriers than in those in the normal-
weight group. These interactive effects between the APOA5 gene and overweight on 
circulating TG levels and arterial stiffness supports the role of circulating TG as one of 
the major inducers of arterial stiffness in overweight/obese subjects [4,39,40]. Recently, 
Guardiola et al. [2] have shown that APOA5 variants predispose hyperlipidemic 
patients to atherogenic dyslipidemia and subclinical atherosclerosis, and this 
observation is significantly stronger in subjects with a BMI ≥25 kg/m2 than in those 
with a normal weight. In this study, a multiple linear regression analysis revealed that 
changes in TG, systolic BP, and LDL particle size were independent determinants of 
the longitudinal progression of arterial stiffness in the subjects in the overweight 
groups. 
The rare APOA5 -1131C alleles were associated with an atherogenic profile 
characterized by high levels of small, dense LDL [2]. Atherogenic changes associated 
with LDL cholesterol induced by TG have been found to occur at concentrations as 
low as 1.7 mmol/L, which is the level at which small, dense LDLs become 
predominant [41]. Recently, Vishnu et al. [8] found that baPWV was significantly 
associated with atherogenic small-sized LDL particles, independent of other 
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cardiovascular risk factors. Takahashi et al. [42] also reported a significant association 
between very small LDL cholesterol and baPWV. Similarly, in the overweight group 
in this study, a change in LDL particle size was one of the independent determinants of 
a change in baPWV. At the 3-year follow-up, overweight subjects with the C allele 
showed smaller LDL particle sizes and lower plasma apo A-V concentrations than 
those with the TT genotype.  
In all subjects, changes in TG were independently affected by APOA5 -1131T>C 
genotype, age, baseline TG level, and changes in BMI and apo A-V levels. There were 
significant negative correlations between changes in TG and plasma apo A-V 
concentrations in overweight individuals with the C allele and in TT carriers. This is in 
contrast to previous observations of significant positive correlations between 
circulating apo A-V and TG levels in men and women [10,11]. These different results 
could be partly explained by difference in study design. In general, previous human 
studies on the relationship between apo A-V and TG levels have been cross-sectional; 
however, the current study was longitudinal.  
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6. CONCLUSIONS 
 
In terms of limitations, this study only included normal-weight and overweight 
subjects without diabetes or cardiovascular diseases; therefore, the present results may 
not extrapolate to subjects who are obese, diabetic or have cardiovascular diseases. 
Despite this limitation, this study found that the longitudinal interaction between 
APOA5 -1131C variants and overweight could accelerate the age-related increase in 
arterial stiffness through the regulation of circulating TG in healthy subjects. Therefore, 
the management of hypertriglyceridemia is important for preventing the progression to 
advanced arterial stiffness, especially in overweight subjects with the APOA5 -1131C 
allele.
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국문요약 
 
노화에 따른 혈관 경직도와 혈류 내 중성지방에  
APOA5 -1131T>C와 과체중의 상호작용이 미치는 영향 
 
연구 목적: 본 연구에서는 건강한 사람을 대상으로 노화에 따른 혈관경직도
의 가속화와 혈류 내 중성지방에 APOA5 -1131T>C와 과체중이 미치는 상관
관계를 알아보기 위해 연구를 진행하였다. 
연구 방법: 3년 추적 코호트 연구로 설계되었으며, 건강한 성인 503명을 정
상체중군 (349명)과 과체중군 (154명) 두 그룹으로 나누어 비교 관찰하였다. 
혈관 경직도는 brachial-ankle PWV (baPWV)을 통하여 측정하였으며, 중성
지방, APOA5 -1131T>C SNP, apo A-V, LDL 입자 크기를 측정하였다.  
연구 결과: C allele (86명)을 지닌 과체중군에서 3년 후, 혈중 중성지방과 
baPWV의 증가를 나타냈다. 또한 과체중군 (154명)에서 혈중 중성지방의 변
화는 risk C allele을 가진 대상자에서 TT 유전자형 (68명)을 가진 대상자보
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다 변화가 더 크게 나타났다. 뿐만 아니라 risk C allele을 가진 과체중군에
서 C allele (181명)을 가진 정상체중군보다 혈중 중성지방 농도가 더 많이 
증가했다. baPWV 변화에서도 risk C allele을 지닌 과체중군에서 C allele을 
가진 정상체중군보다 변화의 폭이 더 컸다. 분석 결과 모든 대상자에서 
baPWV의 변화는 나이, 기준 baPWV, 수축기 혈압의 변화에 영향을 받았으
며, 혈중 중성지방의 변화는 APOA5 -1131T>C 유전자형, 나이, 수축기 혈압
의 변화, 기준 중성지방의 변화 및 BMI와 apo A-V의 변화에 영향을 받는 
것으로 나타났다. 과체중군에서 baPWV의 변화는 수축기 혈압, LDL 입자 
크기 및 중성지방의 변화에 영향을 받았다. 
연구 결론: 본 연구에서는 APOA5 -1131T>C 유전자형과 과체중 사이의 상
호 작용이 건강한 대상자에서 혈중 중성지방 농도에 영향을 미치며, 연령 
증가에 따른 혈관 경직도를 가속화 할 수 있음을 보여준다. 
 
 
 
핵심되는 말 :  APOA5; 혈관경직도; 유전자-환경 상호작용; 과체중; 
중성지방 
 
